Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication

Obesity Clinical Trial

— DIETEVOME  

Official title:

Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication and Their Implication in Atherosclerosis and Metabolic Syndrome: a Multi-omics Approach to Precision Nutrition

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06051461
• Other study ID #: US
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: September 1, 2027

Study information

• Verified date: September 2023
• Source: University of Seville
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dietary interventions have been consistently proposed as a part of a comprehensive strategy to lower the incidence and severity of atherosclerosis and coronary vascular disease. Excessive comsumption of fats enriched in saturated fatty acids (SFAs) is associated with an increased risk of atherosclerosis and other cardiovascular diseases (CVD). In contrasts, replacement of SFAs with monounsaturated fatty acids (MUFAs) and omega-3 long chain polyunsaturated fatty acids (ω3-LCPUFAs) has been reported to be inversely associated with risk of atherosclerosis. This is partly due to the ability of MUFAs (and ω3-LCPUFAs) to modulate lipoprotein composition, oxidation state, and consequently their functionality, among others. While most of the nutritional studies have focused on elucidating the mechanisms by which dietary fats affect lipoprotein particles, little or nothing is known about the regulatory effect of dietary fatty acids on extracellular vesicles (EVs). EVs are small phospholipid particles that convey molecular bioactive cargoes and play essential roles in intercellular communication and, hence, a multifaceted role in health and disease. For the first time, the purpose of this project is to establish whether the type of major fatty acids present on a diet (SFAs, MUFAs, or ω3-LCPUFAs) may alter the structure, cargo, and functionality of postprandial- and long-term-EVs. In the precision nutrition era, the investigators expect to offer a new insight on EVs and their relationship with dietary fatty acids through the following objectives: 1) To map changes in the lipidome, proteome, microtranscriptome, and functional properties of circulating EVs in healthy subjects and patients with metabolic syndrome (MetS) both at fasting and at postprandial state upon a challenge of a meal rich in SFAs, MUFAs, and ω3-LCPUFAs; 2) To analyse the contribution of postprandial triacylglyceride-rich lipoproteins (TRL) on EVs-mediated intercellular communication in a fatty acid-dependent manner; and 3) To determine the influence of diets rich in SFAs, MUFAs, and ω3-LCPUFAs on EVs in an animal model of atherosclerosis in the setting of MetS. Collectively, this project will provide fundamental insight into EV biology, and remarks the clinical and functional relevance and divergent consequences of dietary fatty acids in health and disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: September 1, 2027
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of metabolic syndrome

Exclusion Criteria:

• Allergy to dairy products
• Allergy to fish oil
• Vegetarian
• Tobacco smoker
• Current or recent (<4 wk) use of fish oil supplements or more than four times fish/week
• Received innoculations within 2 mo of starting the study or planned to during the study
• Donated or intended to donate blood from 2 mo before the study till 2 mo after the study
• Unstable body weight (no weight gain/loss >3 kg)

Related Conditions & MeSH terms

• Immune System and Related Disorders
• Inflammation
• Metabolic Diseases
• Metabolic Disorder
• Metabolic Syndrome
• Obesity
• Syndrome

Intervention

Dietary Supplement:
• Oral lipid emulsions
The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (?3-LCPUFAs).

Locations

Country	Name	City	State
Spain	University of Seville	Seville

Sponsors (2)

Lead Sponsor	Collaborator
University of Seville	Spanish National Research Council

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evolution of cytokines in postprandial state	Pro-inflammatory and anti-inflammatory cytokines, including NFa, IL-1ß, IL-6, IL-8, IL-10, ICAM-1, MCP-1, leptin, and adiponectin, in plasma will be measured using appropriate methods (EIA, ELISA, and/or Bioplex multiplex system) (mg/dl).	Up to 6 hours
Primary	Evolution of inflammatory markers in postprandial state. [Time Frame: Up to 6 hours]	The acute phase protein (hsCRP), PAI-1, fibrinogen, transferrin, albumin, and myeloperoxidase (MPO) will be measured using appropriate methods (EIA, ELISA, and/or Bioplex multiplex system) (mg/dl).	Up to 6 hours
Primary	Effect of EVs on gene expression in PBMCs	PBMCs will be isolated from the subjects' peripheral blood and treated with autologous circulating EVs for different times.	Up to 6 hours
Primary	EV proteome	The quantification of exosome-derived proteins will be performed by nLC-MS/MS	Up to 6 hours
Primary	EV lipidome	The analysis of intact lipids derived from exosomes will be performed by LC-MS	Up to 6 hours
Primary	Ev microtranscriptome	Enriched RNA and miRNA derived from exosomes will be determined by Next Generation Sequencing (NGS)	Up to 6 hours